The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Remicade Biosimilar-Global Market Insights and Sales Trends 2025
Synopsis
A Remicade biosimilar is a biologic medication that is highly similar to Remicade, a brand-name biologic used to treat autoimmune diseases such as rheumatoid arthritis, Crohn's disease, and psoriasis.
The global Remicade Biosimilar market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Remicade Biosimilar in various end use industries. The expanding demands from the Blood Disorders and Oncology Diseases, are propelling Remicade Biosimilar market. 100mg/10ml, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the 500mg/50ml segment is estimated at % CAGR for the next seven-year period.
The market for Remicade biosimilars is driven by the increasing demand for cost-effective biologic therapies and the expiration of Remicade's patent, leading to the entry of biosimilar competitors. The market's growth is also influenced by regulatory support for biosimilars and the ongoing development of new biologic therapies.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Remicade Biosimilar, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Remicade Biosimilar market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Remicade Biosimilar market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Remicade Biosimilar sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Remicade Biosimilar covered in this report include Synthon Pharmaceuticals, LG Life Sciences, Novartis (Sandoz), Celltrion, Biocon, Hospira, Merck Serono (Merck Group), Biogen idec Inc. and Genentech (Roche Group), etc.
The global Remicade Biosimilar market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Synthon Pharmaceuticals
LG Life Sciences
Novartis (Sandoz)
Celltrion
Biocon
Hospira
Merck Serono (Merck Group)
Biogen idec Inc.
Genentech (Roche Group)
Fosun Pharmaceutical
Livzon Pharmaceutical
Anke Biotechnology
Hualan Biological Engineering
Walvax Biotechnology
Hisun Pharmaceutical
Global Remicade Biosimilar market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Remicade Biosimilar market, Segment by Type:
100mg/10ml
500mg/50ml
Global Remicade Biosimilar market, by Application
Blood Disorders
Oncology Diseases
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Remicade Biosimilar manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Remicade Biosimilar in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
A Remicade biosimilar is a biologic medication that is highly similar to Remicade, a brand-name biologic used to treat autoimmune diseases such as rheumatoid arthritis, Crohn's disease, and psoriasis.
The global Remicade Biosimilar market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Remicade Biosimilar in various end use industries. The expanding demands from the Blood Disorders and Oncology Diseases, are propelling Remicade Biosimilar market. 100mg/10ml, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the 500mg/50ml segment is estimated at % CAGR for the next seven-year period.
The market for Remicade biosimilars is driven by the increasing demand for cost-effective biologic therapies and the expiration of Remicade's patent, leading to the entry of biosimilar competitors. The market's growth is also influenced by regulatory support for biosimilars and the ongoing development of new biologic therapies.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Remicade Biosimilar, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Remicade Biosimilar market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Remicade Biosimilar market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Remicade Biosimilar sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Remicade Biosimilar covered in this report include Synthon Pharmaceuticals, LG Life Sciences, Novartis (Sandoz), Celltrion, Biocon, Hospira, Merck Serono (Merck Group), Biogen idec Inc. and Genentech (Roche Group), etc.
The global Remicade Biosimilar market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Synthon Pharmaceuticals
LG Life Sciences
Novartis (Sandoz)
Celltrion
Biocon
Hospira
Merck Serono (Merck Group)
Biogen idec Inc.
Genentech (Roche Group)
Fosun Pharmaceutical
Livzon Pharmaceutical
Anke Biotechnology
Hualan Biological Engineering
Walvax Biotechnology
Hisun Pharmaceutical
Global Remicade Biosimilar market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Remicade Biosimilar market, Segment by Type:
100mg/10ml
500mg/50ml
Global Remicade Biosimilar market, by Application
Blood Disorders
Oncology Diseases
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Remicade Biosimilar manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Remicade Biosimilar in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 Remicade Biosimilar Market Overview
1.1 Remicade Biosimilar Product Overview
1.2 Remicade Biosimilar Market Segment by Type
1.2.1 100mg/10ml
1.2.2 500mg/50ml
1.3 Global Remicade Biosimilar Market Size by Type
1.3.1 Global Remicade Biosimilar Market Size Overview by Type (2018-2029)
1.3.2 Global Remicade Biosimilar Historic Market Size Review by Type (2018-2023)
1.3.3 Global Remicade Biosimilar Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Remicade Biosimilar Sales Breakdown by Type (2018-2023)
1.4.2 Europe Remicade Biosimilar Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Remicade Biosimilar Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Remicade Biosimilar Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Remicade Biosimilar Sales Breakdown by Type (2018-2023)
2 Global Remicade Biosimilar Market Competition by Company
2.1 Global Top Players by Remicade Biosimilar Sales (2018-2023)
2.2 Global Top Players by Remicade Biosimilar Revenue (2018-2023)
2.3 Global Top Players by Remicade Biosimilar Price (2018-2023)
2.4 Global Top Manufacturers Remicade Biosimilar Manufacturing Base Distribution, Sales Area, Product Type
2.5 Remicade Biosimilar Market Competitive Situation and Trends
2.5.1 Remicade Biosimilar Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Remicade Biosimilar Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Remicade Biosimilar as of 2022)
2.7 Date of Key Manufacturers Enter into Remicade Biosimilar Market
2.8 Key Manufacturers Remicade Biosimilar Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Remicade Biosimilar Status and Outlook by Region
3.1 Global Remicade Biosimilar Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Remicade Biosimilar Historic Market Size by Region
3.2.1 Global Remicade Biosimilar Sales in Volume by Region (2018-2023)
3.2.2 Global Remicade Biosimilar Sales in Value by Region (2018-2023)
3.2.3 Global Remicade Biosimilar Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Remicade Biosimilar Forecasted Market Size by Region
3.3.1 Global Remicade Biosimilar Sales in Volume by Region (2024-2029)
3.3.2 Global Remicade Biosimilar Sales in Value by Region (2024-2029)
3.3.3 Global Remicade Biosimilar Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Remicade Biosimilar by Application
4.1 Remicade Biosimilar Market Segment by Application
4.1.1 Blood Disorders
4.1.2 Oncology Diseases
4.2 Global Remicade Biosimilar Market Size by Application
4.2.1 Global Remicade Biosimilar Market Size Overview by Application (2018-2029)
4.2.2 Global Remicade Biosimilar Historic Market Size Review by Application (2018-2023)
4.2.3 Global Remicade Biosimilar Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Remicade Biosimilar Sales Breakdown by Application (2018-2023)
4.3.2 Europe Remicade Biosimilar Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Remicade Biosimilar Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Remicade Biosimilar Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Remicade Biosimilar Sales Breakdown by Application (2018-2023)
5 North America Remicade Biosimilar by Country
5.1 North America Remicade Biosimilar Historic Market Size by Country
5.1.1 North America Remicade Biosimilar Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Remicade Biosimilar Sales in Volume by Country (2018-2023)
5.1.3 North America Remicade Biosimilar Sales in Value by Country (2018-2023)
5.2 North America Remicade Biosimilar Forecasted Market Size by Country
5.2.1 North America Remicade Biosimilar Sales in Volume by Country (2024-2029)
5.2.2 North America Remicade Biosimilar Sales in Value by Country (2024-2029)
6 Europe Remicade Biosimilar by Country
6.1 Europe Remicade Biosimilar Historic Market Size by Country
6.1.1 Europe Remicade Biosimilar Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Remicade Biosimilar Sales in Volume by Country (2018-2023)
6.1.3 Europe Remicade Biosimilar Sales in Value by Country (2018-2023)
6.2 Europe Remicade Biosimilar Forecasted Market Size by Country
6.2.1 Europe Remicade Biosimilar Sales in Volume by Country (2024-2029)
6.2.2 Europe Remicade Biosimilar Sales in Value by Country (2024-2029)
7 Asia-Pacific Remicade Biosimilar by Region
7.1 Asia-Pacific Remicade Biosimilar Historic Market Size by Region
7.1.1 Asia-Pacific Remicade Biosimilar Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Remicade Biosimilar Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Remicade Biosimilar Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Remicade Biosimilar Forecasted Market Size by Region
7.2.1 Asia-Pacific Remicade Biosimilar Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Remicade Biosimilar Sales in Value by Region (2024-2029)
8 Latin America Remicade Biosimilar by Country
8.1 Latin America Remicade Biosimilar Historic Market Size by Country
8.1.1 Latin America Remicade Biosimilar Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Remicade Biosimilar Sales in Volume by Country (2018-2023)
8.1.3 Latin America Remicade Biosimilar Sales in Value by Country (2018-2023)
8.2 Latin America Remicade Biosimilar Forecasted Market Size by Country
8.2.1 Latin America Remicade Biosimilar Sales in Volume by Country (2024-2029)
8.2.2 Latin America Remicade Biosimilar Sales in Value by Country (2024-2029)
9 Middle East and Africa Remicade Biosimilar by Country
9.1 Middle East and Africa Remicade Biosimilar Historic Market Size by Country
9.1.1 Middle East and Africa Remicade Biosimilar Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Remicade Biosimilar Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Remicade Biosimilar Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Remicade Biosimilar Forecasted Market Size by Country
9.2.1 Middle East and Africa Remicade Biosimilar Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Remicade Biosimilar Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Synthon Pharmaceuticals
10.1.1 Synthon Pharmaceuticals Company Information
10.1.2 Synthon Pharmaceuticals Introduction and Business Overview
10.1.3 Synthon Pharmaceuticals Remicade Biosimilar Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Synthon Pharmaceuticals Remicade Biosimilar Products Offered
10.1.5 Synthon Pharmaceuticals Recent Development
10.2 LG Life Sciences
10.2.1 LG Life Sciences Company Information
10.2.2 LG Life Sciences Introduction and Business Overview
10.2.3 LG Life Sciences Remicade Biosimilar Sales, Revenue and Gross Margin (2018-2023)
10.2.4 LG Life Sciences Remicade Biosimilar Products Offered
10.2.5 LG Life Sciences Recent Development
10.3 Novartis (Sandoz)
10.3.1 Novartis (Sandoz) Company Information
10.3.2 Novartis (Sandoz) Introduction and Business Overview
10.3.3 Novartis (Sandoz) Remicade Biosimilar Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Novartis (Sandoz) Remicade Biosimilar Products Offered
10.3.5 Novartis (Sandoz) Recent Development
10.4 Celltrion
10.4.1 Celltrion Company Information
10.4.2 Celltrion Introduction and Business Overview
10.4.3 Celltrion Remicade Biosimilar Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Celltrion Remicade Biosimilar Products Offered
10.4.5 Celltrion Recent Development
10.5 Biocon
10.5.1 Biocon Company Information
10.5.2 Biocon Introduction and Business Overview
10.5.3 Biocon Remicade Biosimilar Sales, Revenue and Gross Margin (2018-2023)
10.5.4 Biocon Remicade Biosimilar Products Offered
10.5.5 Biocon Recent Development
10.6 Hospira
10.6.1 Hospira Company Information
10.6.2 Hospira Introduction and Business Overview
10.6.3 Hospira Remicade Biosimilar Sales, Revenue and Gross Margin (2018-2023)
10.6.4 Hospira Remicade Biosimilar Products Offered
10.6.5 Hospira Recent Development
10.7 Merck Serono (Merck Group)
10.7.1 Merck Serono (Merck Group) Company Information
10.7.2 Merck Serono (Merck Group) Introduction and Business Overview
10.7.3 Merck Serono (Merck Group) Remicade Biosimilar Sales, Revenue and Gross Margin (2018-2023)
10.7.4 Merck Serono (Merck Group) Remicade Biosimilar Products Offered
10.7.5 Merck Serono (Merck Group) Recent Development
10.8 Biogen idec Inc.
10.8.1 Biogen idec Inc. Company Information
10.8.2 Biogen idec Inc. Introduction and Business Overview
10.8.3 Biogen idec Inc. Remicade Biosimilar Sales, Revenue and Gross Margin (2018-2023)
10.8.4 Biogen idec Inc. Remicade Biosimilar Products Offered
10.8.5 Biogen idec Inc. Recent Development
10.9 Genentech (Roche Group)
10.9.1 Genentech (Roche Group) Company Information
10.9.2 Genentech (Roche Group) Introduction and Business Overview
10.9.3 Genentech (Roche Group) Remicade Biosimilar Sales, Revenue and Gross Margin (2018-2023)
10.9.4 Genentech (Roche Group) Remicade Biosimilar Products Offered
10.9.5 Genentech (Roche Group) Recent Development
10.10 Fosun Pharmaceutical
10.10.1 Fosun Pharmaceutical Company Information
10.10.2 Fosun Pharmaceutical Introduction and Business Overview
10.10.3 Fosun Pharmaceutical Remicade Biosimilar Sales, Revenue and Gross Margin (2018-2023)
10.10.4 Fosun Pharmaceutical Remicade Biosimilar Products Offered
10.10.5 Fosun Pharmaceutical Recent Development
10.11 Livzon Pharmaceutical
10.11.1 Livzon Pharmaceutical Company Information
10.11.2 Livzon Pharmaceutical Introduction and Business Overview
10.11.3 Livzon Pharmaceutical Remicade Biosimilar Sales, Revenue and Gross Margin (2018-2023)
10.11.4 Livzon Pharmaceutical Remicade Biosimilar Products Offered
10.11.5 Livzon Pharmaceutical Recent Development
10.12 Anke Biotechnology
10.12.1 Anke Biotechnology Company Information
10.12.2 Anke Biotechnology Introduction and Business Overview
10.12.3 Anke Biotechnology Remicade Biosimilar Sales, Revenue and Gross Margin (2018-2023)
10.12.4 Anke Biotechnology Remicade Biosimilar Products Offered
10.12.5 Anke Biotechnology Recent Development
10.13 Hualan Biological Engineering
10.13.1 Hualan Biological Engineering Company Information
10.13.2 Hualan Biological Engineering Introduction and Business Overview
10.13.3 Hualan Biological Engineering Remicade Biosimilar Sales, Revenue and Gross Margin (2018-2023)
10.13.4 Hualan Biological Engineering Remicade Biosimilar Products Offered
10.13.5 Hualan Biological Engineering Recent Development
10.14 Walvax Biotechnology
10.14.1 Walvax Biotechnology Company Information
10.14.2 Walvax Biotechnology Introduction and Business Overview
10.14.3 Walvax Biotechnology Remicade Biosimilar Sales, Revenue and Gross Margin (2018-2023)
10.14.4 Walvax Biotechnology Remicade Biosimilar Products Offered
10.14.5 Walvax Biotechnology Recent Development
10.15 Hisun Pharmaceutical
10.15.1 Hisun Pharmaceutical Company Information
10.15.2 Hisun Pharmaceutical Introduction and Business Overview
10.15.3 Hisun Pharmaceutical Remicade Biosimilar Sales, Revenue and Gross Margin (2018-2023)
10.15.4 Hisun Pharmaceutical Remicade Biosimilar Products Offered
10.15.5 Hisun Pharmaceutical Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Remicade Biosimilar Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Remicade Biosimilar Industrial Chain Analysis
11.4 Remicade Biosimilar Market Dynamics
11.4.1 Remicade Biosimilar Industry Trends
11.4.2 Remicade Biosimilar Market Drivers
11.4.3 Remicade Biosimilar Market Challenges
11.4.4 Remicade Biosimilar Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Remicade Biosimilar Distributors
12.3 Remicade Biosimilar Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
